46963.1 IP-LS

Résumé

Microfluidic-based direct identification of virus-neutralizing antibodies from comprehensive B-cell repertoires of elite controllers of infection (##DIVA#) for a rapid anti-pandemic response

Textes supplémentaires

Abstract

The innovative microfluidic screening platform #DIVA will allow direct discovery of neutralizing antibodies against viral infections and thus shorten the drug development process. It will be benchmarked with the current pandemic SARS-CoV-2 and applied to the discovery of CMV-neutralizing antibodies.

Participants

Christoph Esslinger

Wirtschaftspartner

christoph.esslinger@memo-therapeutics.com

Memo Therapeutics AG c/o D-BSSE / ETH Zürich CHE-428.742.263 Christoph Esslinger Otto-Stern-Weg 7 8093 Zürich ZH CH

Sven Panke

Kontaktperson

sven.panke@bsse.ethz.ch

ETH Zürich department of biosystems science an D-BSSE Sven Panke Mattenstrasse 26 4058 Basel BS CH

Détails du projet

Office de recherche: INNOSUISSE
Statut du projet: Abgeschlossen
Type de projet: Forschungsprojekt
Date de début: 2020-10-31
Date de fin: 2022-10-31
Coûts totaux approuvés: CHF 383463.83
Section: 60 Life Sciences
Domaine politique NABS: Industrielle Produktivität und Technologie

Disciplines de recherche

T410 Pharmaceuticals and related technologies 100.0%